Immunotherapy

PD-1 Monoclonal Antibodies Usher in the Era of Immunotherapy in Oncology

Immunotherapy, Personalized Medicine

September 2014, Vol 5, No 7

Oncologists’ excitement about the promise of immunotherapy is about to be tested in clinical practice, with the recent FDA approval of pembrolizumab (Kytruda; Merck), the first anti–programmed death receptor-1 (PD-1) monoclonal antibody

Page 6 of 6

3
4
5
6